FindTrial
Sign In

RO5024048

DRUG11 trials

Sponsors

Pharmasset, Hoffmann-La Roche

Conditions

Healthy VolunteerHealthy VolunteersHepatitis C VirusHepatitis C, Chronic

Phase 1

Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin
CompletedNCT00382798
PharmassetHealthy Volunteers, Hepatitis C Virus
Start: 2006-10-31End: 2008-09-30Target: 75Updated: 2009-04-27
A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients
CompletedNCT00801255
Hoffmann-La RocheHepatitis C, Chronic
Start: 2008-11-30End: 2010-03-31Updated: 2016-11-02
A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048
CompletedNCT01099904
Hoffmann-La RocheHealthy Volunteer
Start: 2010-03-31End: 2010-09-30Updated: 2016-11-02
A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers
CompletedNCT01152671
Hoffmann-La RocheHealthy Volunteer
Start: 2010-06-30End: 2010-08-31Updated: 2016-11-02

Phase 2

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4
CompletedNCT00869661
Hoffmann-La RocheHepatitis C, Chronic
Start: 2001-02-28End: 2012-02-29Updated: 2016-11-02
A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4
CompletedNCT01057667
Hoffmann-La RocheHepatitis C, Chronic
Start: 2010-02-28End: 2012-04-30Updated: 2016-11-02
A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)
CompletedNCT01278134
Hoffmann-La RocheHepatitis C, Chronic
Start: 2011-02-28End: 2012-10-31Updated: 2016-11-02
A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C
CompletedNCT01331850
Hoffmann-La RocheHepatitis C, Chronic
Start: 2011-05-31End: 2013-01-31Updated: 2016-11-02
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
CompletedNCT01483742
Hoffmann-La RocheHepatitis C, Chronic
Start: 2012-04-30End: 2013-09-30Updated: 2016-08-01
A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment
WithdrawnNCT01579019
Hoffmann-La RocheHepatitis C, Chronic
Start: 2012-07-31End: 2014-03-31Updated: 2016-11-02
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
CompletedNCT01628094
Hoffmann-La RocheHepatitis C, Chronic
Start: 2012-06-30End: 2013-11-30Updated: 2016-11-02

Related Papers

Identification of the NS5B S282T Resistant Variant and Two Novel Amino Acid Substitutions That Affect Replication Capacity in Hepatitis C Virus-Infected Patients Treated with Mericitabine and Danoprevir
Antimicrobial Agents and Chemotherapy2014-03-1817 citations
In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir
The Journal of Infectious Diseases2013-10-23116 citations
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
2010-10-14228 citations